17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation Leukemia (2009) Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, but the fundamental genetic abnormalities underlying this disease remain elusive. The clinical course is variable with a survival ranging from 2 to more than 15 years. Many clinical (for example, stage and lymphocyte doubling time) and biological (for example, mutational status, CD38, ZAP-70 expression) factors are known to predict clinical outcome. The strongest single predictor is a deletion of chromosome 17p13, 1,2 involving TP53, a tumor suppressor gene that is involved in cell cycling and cell death. 3 This deletion is found in approximately 7% of CLL patients and is associated with a refractory response to chemotherapy and a median survival of only 32 months. 1, 2 MicroRNAs are small non-coding RNAs that regulate the translation of protein-coding mRNAs and thereby protein expression. Numerous microRNAs have been linked with human disease and cancer. Recently, it has been shown in several studies that microRNA-34 is a direct transcriptional target of TP53 and that microRNA-34 downregulates the expression of several TP53 downstream targets. Furthermore, microRNA-34 has found to be downregulated in several types of cancer. 4, 5 In this study, we hypothesized that 17p13/TP53 deletion in patients with CLL is associated with the decreased microRNA-34 expression.
Chronic lymphocytic leukemia patients were clinically diagnosed according to the World Health Organization criteria. 6 Twenty-six patients were selected based on 17p13/TP53 deletion status (Table 1) , as determined by the interphase fluorescence in situ hybridization analysis using a commercially available DNA probe LSI p53 (Vysis, Downers Grove, IL, USA). Total RNA of cryopreserved peripheral blood mononuclear cells was extracted using Trizol reagent according to manufacturer's protocol (Invitrogen, Breda, The Netherlands). Quality control of RNA was done using RNA 6000 Nano assay on the Agilent 2100 Bioanalyser (Agilent, Palo Alto, CA, USA), and all RNA samples showed high quality. Quantitative RT-PCR for mature microRNAs was performed as described by the manufacturer (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Small nucleolar RNAs (RNU24 and RNU66) were used for normalization and relative expression levels, and were determined using the 2 ÀDDCt method (compared with an average expression level of the patients without TP53 deletion).
The expression of microRNA-34a is significantly (Po0.0001; non-parametric Mann-Whitney U-test) downregulated in CLL patients carrying 17p13/TP53 deletions compared with patients without such deletions ( Figure 1 ) and microRNA-34a downregulation is not associated with an immunoglobulin heavy chain variable region gene (IGHV) mutation status (Table 1 ). In one sample (H03-1068), we found relatively high expression levels of microRNA-34a as compared with the other samples with 17p13/ TP53 deletions. We performed sequencing of the complete TP53 coding sequence (exons 2-11) of the remaining second allele as described earlier 7 and found a nucleotide change 736A4G in exon 7, which is a known TP53-inactivating mutation. Furthermore, TP53 was sequenced in two samples (H01-0985 and H03-0818) with relatively low expression of microRNA-34a as compared with the other samples without 17p13/TP53 deletions. However, no genetic alterations could be detected in these patients suggesting that other factors besides TP53 may be involved in the regulation of microRNA-34a expression.
We also investigated the relative expression levels of microRNA-34b and microRNA-34c, but expression of these microRNAs was not detectable (C t values above 35). One of the predicted targets of microRNA-34a, which has been experimentally validated in other cell types, is BCL2 mRNA, 4 resulting in the downregulation of translation and BCL2 protein levels. Therefore, flow cytometric immunophenotyping was used to investigate intracellular BCL2 protein levels in CLL patients with and without 17p13/TP53 deletion. Flow cytometry was largely performed as described earlier 8 to determine the intracellular BCL2 expression levels. Peripheral blood mononuclear cells were stained with a combination of CyBCL2-FITC, CD20-PE, CD45-PerCP, CD5-APC, CD19-APC Cy7 and CD3-PE Cy7 monoclonal antibodies (all from BD Biosciences, San Jose, CA, USA except for CyBCL2-FITC, which was from DAKO, Glostrup, Denmark). However, no difference in BCL2 expression could be detected between CLL patients with and without 17p13/TP53 deletion (data not shown). This suggests that in primary CLL cells as well other factors are involved in the regulation of BCL2 protein expression. Furthermore, other validated targets of microRNA-34a could be involved in a functional relationship between microRNA-34a and CLL.
MicroRNA-34a expression was earlier shown to be reduced in neuroblastoma primary tumors as compared with the normal Number of patients carrying a 13q14 deletion. Letters to the Editor adrenal gland tissue, 5 and microRNA-34b expression was reported to be decreased in non-small-cell lung cancers. 4 Here, we show for the first time that microRNA-34a is significantly downregulated in CLL patients with TP53 deletions compared with CLL patients without such deletions. In these cases, we were not able to reveal BCL2 as a target of microRNA34a. Still, BCL2 being only one of the microRNA-34a targets, a potential function of a regulatory circuit involving the important tumor suppressor TP53 and microRNA-34a in the pathogenesis of CLL cannot be excluded, and needs to be further investigated. 
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